Founded in 2013, PillPack uses a hybrid of automation and good old-fashioned human pharmacists to disrupt the drugstore business. And as of today, it belongs to the e-commerce giant.
The pill problem: Managing prescription medications is a hassle for patients and can be mind-numbing for pharmacists, who spend a lot of time counting pills—time that could be better spent managing people’s health. The consequences of not taking pills properly (and Americans are really bad at taking their pills properly) can be dire.
Pack ’em up: The idea behind PillPack is simple: using staff pharmacists, software, and a dash of computer vision, the company manages a patient’s prescriptions and pre-sorts the pills into little packs stamped with the date and time when they’re supposed to be taken. They’re then shipped to people’s homes—there’s even a cute little dispenser—all for about the cost of filling a prescription at a local drugstore.
Assimilated by Amazon: When we profiled PillPack last year, the company was looking at $100 million in annual revenue from “tens of thousands” of customers, and it’s raised $118 million in venture backing. So Amazon probably paid a pretty penny for its shiny new apothecary (UPDATE: the Wall Street Journal says Amazon's paying $1 billion in cash). But it will have been worth it if the online retail behemoth can gobble up market share from huge US drugstore chains like CVS and Walgreens.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.